ArticleEndocrine2016
Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.
Article in Endocrine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Osteoporosis in COPD patients: Risk factors and pulmonary rehabilitation.The clinical respiratory journal · 2022Pooled it
- Pooled it
- Article
- Vertebral fractures may occur early in the history of Cushing disease associating with male gender and degree of cortisol secretion.Pituitary · 2026Article
- Vitamin D in the elderly: the phil-rouge in preventing bone, muscle and adipose deterioration?Archives of endocrinology and metabolism · 2025Review
- Review
- Increased risk of osteoporotic fractures and osteoporosis in patients with Addison's disease in Sweden: A nationwide population-based cohort study.Journal of internal medicine · 2025Article
- Screening for endogenous hypercortisolism in patients with osteoporosis and fractures: why, when and how.Journal of endocrinological investigation · 2025Review
- Vitamin D and hip protectors in osteosarcopenia: a combined hip fracture preventing approach.Reviews in endocrine & metabolic disorders · 2025Review
- Hypercalcemia Following Adrenalectomy for Cushing Syndrome in a Patient with Post-Surgical Hypoparathyroidism.Diseases (Basel, Switzerland) · 2025Article
- Progress in multiaxial coupling mechanisms of osteoporosis: insights from systems medicine on immune-inflammatory interactions, hormonal regulation, and metabolic imbalance.Frontiers in endocrinology · 2025Review
- IGF-1 c.258 A > G synonymous mutation ameliorates senile osteoporosis.Communications biology · 2024Article
- Cushing's disease and bone.Pituitary · 2024Review
- Vitamin D in pituitary driven osteopathies.Pituitary · 2024Review
- New insights into the vitamin D/PTH axis in endocrine-driven metabolic bone diseases.Endocrine · 2024Review
- Vertebral fractures in patients with non-functioning pituitary adenomas - a new frontier?Pituitary · 2024Article
- Diagnosis and therapeutic approach to bone health in patients with hypopituitarism.Reviews in endocrine & metabolic disorders · 2024Review
- Association of sarcopenia and vitamin D deficiency with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis.Clinical rheumatology · 2024Article
- The Sequential Therapy in Osteoporosis.Indian journal of orthopaedics · 2023Review
- Acromegaly and Bone: An Update.Endocrinology and metabolism (Seoul, Korea) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoid-induced osteoporosis is the most frequent form of secondary osteoporosis caused by chronic exposure to glucocorticoid excess. Pathogenesis of glucocorticoid-induced osteoporosis is multifactorial including direct effects of glucocorticoids on bone cells and indirect effects of glucocorticoids on several neuroendocrine and metabolic pathways. Fragility fractures occur early in glucocorticoid-induced osteoporosis and anti-osteoporotic drugs along with calcium and vitamin D should be started soon after exposure to glucocorticoid excess. This paper summarizes some of the main topics discussed during the 9th Glucocorticoid-Induced Osteoporosis Meeting (Rome, April 2016) with a specific focus on the role of growth hormone/insulin-like growth factor-1 and parathyroid hormone/vitamin D axes in the pathogenesis of glucocorticoid-induced osteoporosis and the controversial aspects concerning therapeutic approach to skeletal fragility in this clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.